Olivier Litzka - 27 Apr 2023 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Director
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
27 Apr 2023
Net transactions value
$0
Form type
4
Filing time
01 May 2023, 16:06:21 UTC
Previous filing
13 Feb 2023
Next filing
23 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Other $0 -44,000 -100% $0.000000* 0 27 Apr 2023 Common Stock 44,000 $16.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and BioDiscovery 6 FCPI.
F2 The stock option vests in 36 monthly installments beginning on March 9, 2023.